Gefitinib Tablets 250 mg are an oral, selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
It blocks EGFR‑mediated intracellular signaling, thereby inhibiting tumor cell proliferation, invasion, and angiogenesis, and inducing apoptosis.
Composition
Each film‑coated tablet contains:
Gefitinib …… 250 mg
Indications
First‑line treatment of locally advanced or metastatic non‑small cell lung cancer (NSCLC) with activating EGFR mutations in adult patients.
Key Features
Targeted inhibition of EGFR tyrosine kinase
Once‑daily oral administration
Clinical benefit in EGFR mutation‑positive NSCLC
More tolerable than conventional chemotherapy
Stable formulation suitable for long‑term treatment
Manufactured under GMP conditions
Complies with USP, EP, CP pharmacopoeial standards
Full registration dossiers available for global markets
Storage
Store in a cool, dry place, protected from light and moisture.
Keep out of reach of children.
Important Note
This is a prescription‑only anticancer medicine.
Contraindicated in patients with hypersensitivity to gefitinib.
Common adverse reactions: rash, acne, dry skin, diarrhea, nail disorders.
Monitor liver function regularly during treatment.
Discontinue promptly if interstitial lung disease occurs.
Use only under the supervision of an oncologist.
